• 1
    Ruggeri L, Capanni M, Urbani E et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295 (5562): 20972100.
  • 2
    Nguyen S, Kuentz M, Vernant JP et al. Involvement of mature donor T cells in the NK cell reconstitution after haploidentical hematopoietic stem-cell transplantation. Leukemia 2008; 22 (2): 344352.
  • 3
    Lundqvist A, McCoy JP, Samsel L, Childs R. Reduction of GVHD and enhanced antitumor effects after adoptive infusion of alloreactive Ly49-mismatched NK cells from MHC-matched donors. Blood 2007; 109 (8): 36033606.
  • 4
    Zhang C, Niu J, Zhang J, Wang Y, Zhou Z, Tian Z. Opposing effects of interferon-alpha and interferon-gamma on the expression of major histocompatibility complex class I chain-related A in tumors. Cancer Sci 2008; 99 (6): 12791286.
  • 5
    Diermayr S, Himmelreich H, Durovic B et al. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. Blood 2008; 111 (3): 14281436.
  • 6
    Andresen L, Jensen H, Pedersen MT, Hansen KA, Skov S. Molecular regulation of MHC class I chain-related protein A expression after HDAC-inhibitor treatment of Jurkat T cells. J Immunol 2007; 179 (12): 82358242.
  • 7
    Fuertes MB, Girart MV, Molinero LL et al. Intracellular retention of the NKG2D ligand MHC class I chain-related gene A in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity. J Immunol 2008; 180 (7): 46064614.
  • 8
    Kato N, Tanaka J, Sugita J et al. Regulation of the expression of MHC class I-related chain A, B (MICA, MICB) via chromatin remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells. Leukemia 2007; 21 (10): 21032108.
  • 9
    Poggi A, Catellani S, Garuti A, Pierri I, Gobbi M, Zocchi MR. Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate. Leukemia 2009; 23 (4): 641648.
  • 10
    Soriani A, Zingoni A, Cerboni C et al. ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood 2009; 113 (15): 35033511.
  • 11
    Skov S, Pedersen MT, Andresen L, Straten PT, Woetmann A, Odum N. Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res 2005; 65 (23): 1113611145.
  • 12
    Vales-Gomez M, Chisholm SE, Cassady-Cain RL, Roda-Navarro P, Reyburn HT. Selective induction of expression of a ligand for the NKG2D receptor by proteasome inhibitors. Cancer Res 2008; 68 (5): 15461554.
  • 13
    Pende D, Rivera P, Marcenaro S et al. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res 2002; 62 (21): 61786186.
  • 14
    Armeanu S, Bitzer M, Lauer UM et al. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 2005; 65 (14): 63216329.
  • 15
    Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005; 436 (7054): 11861190.
  • 16
    Cerboni C, Zingoni A, Cippitelli M, Piccoli M, Frati L, Santoni A. Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK- cell lysis. Blood 2007; 110 (2): 606615.
  • 17
    Kobayashi M, Hirano A, Kumano T et al. Critical role for chicken Rad17 and Rad9 in the cellular response to DNA damage and stalled DNA replication. Genes Cells 2004; 9 (4): 291303.
  • 18
    Iwahori S, Yasui Y, Kudoh A et al. Identification of phosphorylation sites on transcription factor Sp1 in response to DNA damage and its accumulation at damaged sites. Cell Signal 2008; 20 (10): 17951803.
  • 19
    Kramer OH, Knauer SK, Zimmermann D, Stauber RH, Heinzel T. Histone deacetylase inhibitors and hydroxyurea modulate the cell cycle and cooperatively induce apoptosis. Oncogene 2008; 27 (6): 732740.
  • 20
    Feng X, Chuhjo T, Sugimori C et al. Diazepam-binding inhibitor-related protein 1: a candidate autoantigen in acquired aplastic anemia patients harboring a minor population of paroxysmal nocturnal hemoglobinuria-type cells. Blood 2004; 104 (8): 24252431.
  • 21
    Lu X, Kondo Y, Takamatsu H et al. CD16+ CD56- NK cells in the peripheral blood of cord blood transplant recipients: a unique subset of NK cells possibly associated with graft-versus-leukemia effect. Eur J Haematol 2008; 81 (1): 1825.
  • 22
    Rohner A, Langenkamp U, Siegler U, Kalberer CP, Wodnar-Filipowicz A. Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis. Leuk Res 2007; 31 (10): 13931402.
  • 23
    Nakao S, Takami A, Takamatsu H et al. Isolation of a T-cell clone showing HLA-DRB1*0405-restricted cytotoxicity for hematopoietic cells in a patient with aplastic anemia. Blood 1997; 89 (10): 36913699.
  • 24
    Rubio V, Stuge TB, Singh N et al. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med 2003; 9 (11): 13771382.
  • 25
    Insinga A, Monestiroli S, Ronzoni S et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 2005; 11 (1): 7176.
  • 26
    Kawagoe R, Kawagoe H, Sano K. Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase-dependent and -independent apoptotic signaling pathways. Leuk Res 2002; 26 (5): 495502.
  • 27
    Kaiser M, Zavrski I, Sterz J et al. The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma. Haematologica 2006; 91 (2): 248251.
  • 28
    Molinero LL, Fuertes MB, Fainboim L, Rabinovich GA, Zwirner NW. Up-regulated expression of MICA on activated T lymphocytes involves Lck and Fyn kinases and signaling through MEK1/ERK, p38 MAP kinase, and calcineurin. J Leukoc Biol 2003; 73 (6): 815822.
  • 29
    Kuendgen A, Gattermann N. Valproic acid for the treatment of myeloid malignancies. Cancer 2007; 110 (5): 943954.
  • 30
    Fruchtman SM. Treatment paradigms in the management of myeloproliferative disorders. Semin Hematol 2004; 41 (2 Suppl 3): 1822.
  • 31
    Thiele J, Kvasnicka HM. Comparative effects of interferon and hydroxyurea on bone marrow fibrosis in chronic myelogenous leukemia. Leuk Lymphoma 2001; 42 (5): 855862.
  • 32
    Motomura S, Sakai R, Tomita N et al. Chronic myelogenous leukemia with long-term hypoplasia induced by alpha-interferon and hydroxyurea. Rinsho Ketsueki 1998; 39 (4): 302307.